Related references
Note: Only part of the references are listed.Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Eloy D. Hernandez et al.
HEPATOLOGY COMMUNICATIONS (2019)
Obesity and nonalcoholic fatty liver disease: current perspectives
Raiya Sarwar et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2018)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
R. Pencek et al.
DIABETES OBESITY & METABOLISM (2016)
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
F. Nevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Farnesoid X Receptor: Good for BAD
Stephen J. Keely et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2016)
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells
Jialin He et al.
MOLECULAR CANCER (2015)
FXR induces SOCS3 and suppresses hepatocellular carcinoma
Fei Guo et al.
ONCOTARGET (2015)
The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice
TinaMarie Lieu et al.
GASTROENTEROLOGY (2014)
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
Howard C. Masuoka et al.
YEAR IN DIABETES AND OBESITY (2013)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
The TGR5 receptor mediates bile acid-induced itch and analgesia
Farzad Alemi et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
The Role of Bile After Roux-en-Y Gastric Bypass in Promoting Weight Loss and Improving Glycaemic Control
Dimitri J. Pournaras et al.
ENDOCRINOLOGY (2012)
Loss of FXR Protects against Diet-Induced Obesity and Accelerates Liver Carcinogenesis in ob/ob Mice
Yanqiao Zhang et al.
MOLECULAR ENDOCRINOLOGY (2012)
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Anna C. Calkin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
Eric T. Sawey et al.
CANCER CELL (2011)
Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations
Gernot Zollner et al.
MOLECULAR PHARMACEUTICS (2006)
FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine
H Lee et al.
JOURNAL OF LIPID RESEARCH (2006)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis
RE Poupon et al.
JOURNAL OF HEPATOLOGY (2003)
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis
G Lambert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation
YQ Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A mouse model of hepatocellular carcinoma - Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
K Nicholes et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
Share Paper
